Chelsea Therapeutics to Present at Rodman & Renshaw 12th Annual Healthcare Conference

CHARLOTTE, N.C., Sept. 8, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Rodman & Renshaw 12th Annual Healthcare Conference at 11:40 AM ET on Wednesday, September 15, 2010 at the New York Palace Hotel in New York City.

Dr. Simon Pedder, Chelsea's president and chief executive officer, will provide a brief overview of the company's product pipeline, clinical development status and upcoming milestones.

Dr. Pedder's presentation will be webcast live and archived for 90 days on Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, NORTHERA™ (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks and costs of drug development including clinical trials and our reliance on our lead drug candidates droxidopa and CH-4051, our need to raise additional operating capital in the future, competition, market acceptance for our products if any are approved for marketing, and reliance on key personnel including specifically Dr. Pedder.

CONTACT: Chelsea Therapeutics
Investor/Media Relations
Kathryn McNeil
704-973-4231